<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; perspective</title>
	<atom:link href="http://www.tapanray.in/tag/perspective/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why And How To Be In-Sync With Gen Z As Pharma Paradigm Shifts?</title>
		<link>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts</link>
		<comments>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/#comments</comments>
		<pubDate>Mon, 21 Feb 2022 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[characteristics]]></category>
		<category><![CDATA[conscious]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Gen Z]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Millenials]]></category>
		<category><![CDATA[minded]]></category>
		<category><![CDATA[natives]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10656</guid>
		<description><![CDATA[As science and technology, across the world, are progressing at a scorching pace &#8211; Covid-19 pandemic notwithstanding, today’s generations are growing up tech savvy &#8211; more than ever before. The trend will keep going north faster and with a steeper &#8230; <a href="http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-and-how-to-be-in-sync-with-gen-z-as-pharma-paradigm-shifts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On Core Competencies &#8211; Regardless of Generic Or Innovative Drug Business</title>
		<link>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business</link>
		<comments>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/#comments</comments>
		<pubDate>Mon, 22 Feb 2021 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carving-out]]></category>
		<category><![CDATA[cephalosporin]]></category>
		<category><![CDATA[cephalosporins]]></category>
		<category><![CDATA[competencies]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[Fortum]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regardless]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[Spin-offs]]></category>
		<category><![CDATA[Splitting-off]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Zinacef]]></category>
		<category><![CDATA[Zinnat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10421</guid>
		<description><![CDATA[On February 11, 2021, by two different Press Releases, two global pharma majors – GSK and Novartis simultaneously made interesting announcements. Both were related to three generic cephalosporin antibiotics. GSK revealed, ‘it has reached an agreement with Sandoz &#8211; a &#8230; <a href="http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-core-competencies-regardless-of-generic-or-innovative-drug-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid-19 Vaccines – A Multifaceted Perspective</title>
		<link>http://www.tapanray.in/covid-19-vaccines-a-multifaceted-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-vaccines-a-multifaceted-perspective</link>
		<comments>http://www.tapanray.in/covid-19-vaccines-a-multifaceted-perspective/#comments</comments>
		<pubDate>Mon, 24 Aug 2020 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[anti-vaccine]]></category>
		<category><![CDATA[bullets]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[cold]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[doubt]]></category>
		<category><![CDATA[feeling]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[movement]]></category>
		<category><![CDATA[Multifaceted]]></category>
		<category><![CDATA[new challenges]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[silver]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10234</guid>
		<description><![CDATA[Even after the destruction of millions of lives, livelihoods, social fabric and national economy of almost all countries – the mayhem of the Coronavirus pandemic continues, unabated. Echoing what many other global experts, the United States National Institute of Allergy and Infectious Diseases Director has &#8230; <a href="http://www.tapanray.in/covid-19-vaccines-a-multifaceted-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-vaccines-a-multifaceted-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Worsening Health Effect Of Climate Change In India: A Perspective</title>
		<link>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=worsening-health-effect-of-climate-change-in-india-a-perspective</link>
		<comments>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/#comments</comments>
		<pubDate>Mon, 14 Dec 2015 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Chennai]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[earth]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[extinction]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[NASA]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[planet]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Race]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[worsening]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7333</guid>
		<description><![CDATA[At present, out of the top five most pressing global and local environmental challenges, ‘Climate Change’ features at the top. It has been broadly defined as, “a change in global or regional climate patterns, in particular a change apparent from &#8230; <a href="http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/worsening-health-effect-of-climate-change-in-india-a-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Indian patients victims of “unnecessary tests and procedures, rewards for referrals and irrational use of drugs?” A perspective</title>
		<link>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective</link>
		<comments>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/#comments</comments>
		<pubDate>Mon, 24 Jan 2011 01:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[procedures]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[referrals]]></category>
		<category><![CDATA[rewards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tests]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unnecessary]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[victims]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=311</guid>
		<description><![CDATA[Since quite some time, serious concerns have been expressed by the media, government and the civil society at large about the means adopted by the pharmaceutical industry in general to get their respective brands prescribed by the doctors and why &#8230; <a href="http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-indian-patients-victims-of-unnecessary-tests-and-procedures-rewards-for-referrals-and-irrational-use-of-drugs-a-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Generics&#8217; Lobby, Innovators&#8217; Lobby and the Pharmaceutical Data Protection in India &#8211; A Perspective</title>
		<link>http://www.tapanray.in/generics-lobby-innovators-lobby-and-the-pharmaceutical-data-protection-in-india-a-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=generics-lobby-innovators-lobby-and-the-pharmaceutical-data-protection-in-india-a-perspective</link>
		<comments>http://www.tapanray.in/generics-lobby-innovators-lobby-and-the-pharmaceutical-data-protection-in-india-a-perspective/#comments</comments>
		<pubDate>Mon, 19 Jul 2010 01:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=400</guid>
		<description><![CDATA[To meet the unmet needs of the patients and improve access to healthcare in India mere discovery of a new pharmaceutical entity is not enough. The journey from mind to market is indeed an arduous one. For the patients’ sake: &#8230; <a href="http://www.tapanray.in/generics-lobby-innovators-lobby-and-the-pharmaceutical-data-protection-in-india-a-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/generics-lobby-innovators-lobby-and-the-pharmaceutical-data-protection-in-india-a-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A brief history of the Indian Patent System from Indian Pharmaceutical Industry perspective, the concerns and opportunities.</title>
		<link>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities</link>
		<comments>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 00:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[brief]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=742</guid>
		<description><![CDATA[Although a comprehensive Act on Patents and Designs allowing product patents of drugs came into force in India in 1911, the first Patents Act of India was enacted in 1856.This Act gave a head start to the global pharmaceutical companies &#8230; <a href="http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Indian and Global Pharmaceutical Industry – A brief perspective to meet the challenge of change</title>
		<link>http://www.tapanray.in/the-indian-and-global-pharmaceutical-industry-a-brief-perspective-to-meet-the-challenge-of-change/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-and-global-pharmaceutical-industry-a-brief-perspective-to-meet-the-challenge-of-change</link>
		<comments>http://www.tapanray.in/the-indian-and-global-pharmaceutical-industry-a-brief-perspective-to-meet-the-challenge-of-change/#comments</comments>
		<pubDate>Mon, 05 Oct 2009 01:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brief]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[meet]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=763</guid>
		<description><![CDATA[A. INDIAN PHARMACEUTICAL INDUSTRY PERSPECTIVE: January 1, 2005 ushered in a paradigm shift in the Indian Pharmaceutical Industry with the new product patent regime. Future of the industry, thereafter, will never be the same again as what we have been &#8230; <a href="http://www.tapanray.in/the-indian-and-global-pharmaceutical-industry-a-brief-perspective-to-meet-the-challenge-of-change/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-and-global-pharmaceutical-industry-a-brief-perspective-to-meet-the-challenge-of-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The stormy debate on wrongful grant of pharma product patents – a countdown of the news events, for a quick perspective.</title>
		<link>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective</link>
		<comments>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/#comments</comments>
		<pubDate>Thu, 12 Mar 2009 16:55:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[countdown]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[news]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Stormy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[wrongful]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=944</guid>
		<description><![CDATA[To give a quick perspective to this debate, I reckon, a countdown of five reported news events on the subject will be helpful. I start from February, 2009 and gradually go one year back, to February, 2008, to capture the &#8230; <a href="http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stormy-debate-on-wrongful-grant-of-pharma-product-patents-a-countdown-of-the-news-events-for-a-quick-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
